Company research
ACCELERON PHARMA INC
CIK 1280600Updated Sep 24, 2026
Securities
Historical securities (1)
XLRN · NASDAQ · equity · closed Nov 19, 2021XLRN price & chart
Historical security
This listing closed Nov 19, 2021. Live provider charts are shown only for current listings.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2020 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 932,337,000Source | 504,906,000Source | 314,821,000Source | 389,177,000Source |
| Property, Plant and Equipment, NetUSD | 7,768,000Source | 6,812,000Source | 7,106,000Source | 6,966,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 670,952,000Source | 237,677,000Source | 144,052,000Source | 100,150,000Source |
| Assets, CurrentUSD | 893,269,000Source | 449,916,000Source | 306,013,000Source | 285,243,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 17,265,000Source | 10,000,000Source | 7,662,000Source | 4,446,000Source |
| Operating Lease, Right-of-Use AssetUSD | 21,988,000Source | 23,908,000Source | — | — |
| Other Assets, NoncurrentUSD | 1,727,000Source | 1,793,000Source | 105,000Source | 113,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 77,230,000Source | 55,430,000Source | 22,784,000Source | 23,960,000Source |
| Commitments and ContingenciesUSD | 0Source | 0Source | 0Source | 0Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 60,000Source | 53,000Source | 47,000Source | 46,000Source |
| Additional Paid in CapitalUSD | 1,732,772,000Source | 1,160,807,000Source | 879,099,000Source | 839,090,000Source |
| Retained Earnings (Accumulated Deficit)USD | -877,437,000Source | -711,407,000Source | -586,549,000Source | -473,024,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -288,000Source | 23,000Source | -560,000Source | -895,000Source |
| Stockholders' Equity Attributable to ParentUSD | 855,107,000Source | 449,476,000Source | 292,037,000Source | 365,217,000Source |
| Liabilities and EquityUSD | 932,337,000Source | 504,906,000Source | 314,821,000Source | 389,177,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 60,163,000Source | 33,373,000Source | 18,912,000Source | 16,745,000Source |
| Operating Lease, Liability, CurrentUSD | 7,010,000Source | 6,183,000Source | — | — |
| Accounts Payable, CurrentUSD | 8,472,000Source | 2,295,000Source | 419,000Source | 1,086,000Source |
| Operating Lease, Liability, NoncurrentUSD | 17,067,000Source | 20,201,000Source | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 44,681,000Source | 24,895,000Source | 18,209,000Source | 14,936,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | 541,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | — | 3,161,000Source |
| Short-term InvestmentsUSD | 178,951,000Source | 193,692,000Source | 147,260,000Source | 177,077,000Source |
cash flow · annual statements
| Line item | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 3,845,000Source | 3,941,000Source | 3,747,000Source | 2,825,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 30,237,000Source | 22,995,000Source | 24,569,000Source | 28,248,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 5,830,000Source | 1,876,000Source | -673,000Source | -504,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -130,327,000Source | -93,804,000Source | -94,706,000Source | -76,730,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 25,596,000Source | -71,291,000Source | 122,927,000Source | -64,366,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 4,203,000Source | 3,287,000Source | 2,590,000Source | 4,396,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | 731,000Source | 226,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 538,006,000Source | 258,720,000Source | 16,146,000Source | 220,296,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 433,275,000Source | 93,625,000Source | 44,367,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 672,549,000Source | 239,274,000Source | 145,649,000Source | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 30,237,000Source | 22,995,000Source | 24,569,000Source | 28,248,000Source |
| General and Administrative ExpenseUSD | — | — | 34,503,000Source | 33,738,000Source |
| Income Tax Expense (Benefit)USD | 21,000Source | -62,000Source | -27,000Source | 32,000Source |
| Investment Income, InterestUSD | — | — | 5,568,000Source | 2,553,000Source |
| Net Income (Loss) Attributable to ParentUSD | -166,030,000Source | -124,858,000Source | -118,871,000Source | -108,454,000Source |
| Nonoperating Income (Expense)USD | 1,297,000Source | 11,525,000Source | 5,516,000Source | 1,561,000Source |
| Operating Lease, ExpenseUSD | 8,200,000Source | 8,200,000Source | — | — |
| Other Nonoperating Income (Expense)USD | -1,576,000Source | 819,000Source | -52,000Source | -992,000Source |
| Proceeds from Issuance of Common StockUSD | 492,414,000Source | 248,130,000Source | 0Source | 215,802,000Source |
income statement · annual statements
| Line item | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|
| Total RevenueUSD | 92,523,000Source | 73,993,000Source | 13,991,000Source | 13,481,000Source |
| Selling, General and Administrative ExpenseUSD | 85,912,000Source | 56,485,000Source | — | — |
| Operating Income (Loss)USD | -167,306,000Source | -136,445,000Source | -124,414,000Source | -109,983,000Source |
| Other Nonoperating Income (Expense)USD | -1,576,000Source | 819,000Source | -52,000Source | -992,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -166,009,000Source | -124,920,000Source | -118,898,000Source | -108,422,000Source |
| Income Tax Expense (Benefit)USD | 21,000Source | -62,000Source | -27,000Source | 32,000Source |
| Net Income (Loss) Attributable to ParentUSD | -166,030,000Source | -124,858,000Source | -118,871,000Source | -108,454,000Source |
| Additional Financial Items | ||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0Source | 0Source | 0Source | 0Source |
| Costs and ExpensesUSD | 259,829,000Source | 210,438,000Source | 138,405,000Source | 123,464,000Source |
| General and Administrative ExpenseUSD | — | — | 34,503,000Source | 33,738,000Source |
| Interest Income, OtherUSD | 2,873,000Source | 10,706,000Source | — | — |
| Investment Income, InterestUSD | — | — | 5,568,000Source | 2,553,000Source |
| Nonoperating Income (Expense)USD | 1,297,000Source | 11,525,000Source | 5,516,000Source | 1,561,000Source |
| Operating Lease, ExpenseUSD | 8,200,000Source | 8,200,000Source | — | — |
| Research and Development ExpenseUSD | 173,917,000Source | 153,953,000Source | 103,902,000Source | 89,726,000Source |